/

Società

Fu

Non verificato

Fujirebio

Di cosa scriviamo

BiotecnologiaIndustriaSaluteSanitàScienza

11 comunicati stampa

Guarda tutti i comunicati

23/06/2025

Scienza

Finanza

Associazioni/Professionisti

Biotecnologia

Salute

Mercato azionario

Industria

Fujirebio Acquires Plasma Services Group and Strengthens Its Position as Provider of Critical and High Quality Biological Raw Materials to the IVD and Life Science Industries

Fonte

Emittente

1.00

0

05/06/2025

Mercato del lavoro

Industria

Salute

HIV, AIDS e malattie autoimmuni

Scienza

Farmaceutica

Biotecnologia

Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research

Fonte

Emittente

1.00

0

04/06/2025

Industria

Psichiatria

Salute

Attrezzature medico-sanitarie

Biotecnologia

Sanità

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only

Fonte

Emittente

1.00

0

17/05/2025

Industria

Biotecnologia

Salute

Attrezzature medico-sanitarie

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

Fonte

Emittente

1.00

0

23/04/2025

Multimedialità

Industria

Salute

HIV, AIDS e malattie autoimmuni

Scienza

Farmaceutica

Biotecnologia

Grant Award from GHIT Fund for Development of an Ultrasensitive Urine Test for Tuberculosis

Fonte

Emittente

1.00

0

18/03/2025

Industria

Sanità

Attrezzature medico-sanitarie

HIV, AIDS e malattie autoimmuni

Salute

Fujirebio Europe Launches the INNO-LiPA® HCV 2.0 Genotyping Assay, an Efficient Aid to Personalized HCV Therapy

Fonte

Emittente

1.00

0

23/12/2024

Biotecnologia

Industria

Sanità

Salute

Oncologia

Scienza

Mercato del lavoro

Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases

Fonte

Emittente

1.00

0

28/10/2024

ADx NeuroSciences and Alamar Biosciences Announce Partnership to Provide Customized Blood-Based Biomarker Assay Solutions to Accelerate Biopharma Clinical Development

Fonte

Emittente

1.00

0

25/09/2024

Industria

Igiene alimentare

Salute

Sanità

Farmaceutica

Biotecnologia

Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

Fonte

Emittente

1.00

0

30/07/2024

Psichiatria

Scienza

Attrezzature medico-sanitarie

Medicina - Varie

Biotecnologia

Sanità

Salute

Mercato del lavoro

Industria

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0